Ryan J. Sullivan
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Colorectal Cancer Treatments and Studies
- Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 271
- Cancer Immunotherapy and Biomarkers 160
- CAR-T cell therapy research 90
- Cutaneous Melanoma Detection and Management 40
- Colorectal Cancer Treatments and Studies 30
-
- Melanoma and MAPK Pathways 116
- Co-authors
- Keith T. Flaherty (80 shared papers)Donald P. Lawrence (70 shared papers)Douglas B. Johnson (39 shared papers)Kerry L. Reynolds (54 shared papers)Justine V. Cohen (41 shared papers)Jeffrey S. Weber (21 shared papers)Alexander M. Menzies (17 shared papers)Alexander T. Faje (4 shared papers)
- Journals
- Journal of Clinical Oncology (106 papers)Journal for ImmunoTherapy of Cancer (20 papers)Cancer Research (18 papers)The Oncologist (15 papers)Annals of Oncology (11 papers)
- Partner nations
- United StatesAustraliaGermany
In The Last Decade
Ryan J. Sullivan
374 papers receiving 13.7k citations
Ryan J. Sullivan's Hit Papers
Peers
Comparison fields: 5 of 146
- Oncology 8.6k
- Immunology 2.8k
- Genetics 633
- Cancer Research 836
- Pulmonary and Respiratory Medicine 1.6k
Countries citing papers authored by Ryan J. Sullivan
This map shows the geographic impact of Ryan J. Sullivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan J. Sullivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan J. Sullivan more than expected).
Fields of papers citing papers by Ryan J. Sullivan
This network shows the impact of papers produced by Ryan J. Sullivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan J. Sullivan. The network helps show where Ryan J. Sullivan may publish in the future.
Co-authors
The 25 scholars most cited alongside Ryan J. Sullivan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 402 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Myocarditis in Patients Treated With Immune Checkpoint Inhibitors Hit paper breakdown → | 2018 | 1096 |
| 2 | Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab Hit paper breakdown → | 2016 | 611 |
| 3 | Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma Hit paper breakdown → | 2018 | 465 |
| 4 | Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque Hit paper breakdown → | 2020 | 381 |
| 5 | Clusters of circulating tumor cells traverse capillary-sized vessels Hit paper breakdown → | 2016 | 375 |
| 6 | Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma Hit paper breakdown → | 2014 | 370 |
| 7 | High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma Hit paper breakdown → | 2018 | 356 |
| 8 | Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy Hit paper breakdown → | 2020 | 327 |
| 9 | 2013 | 272 | |
| 10 | Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies Hit paper breakdown → | 2016 | 269 |
| 11 | 2017 | 264 | |
| 12 | 2016 | 260 | |
| 13 | 2019 | 208 | |
| 14 | 2016 | 201 | |
| 15 | Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies Hit paper breakdown → | 2021 | 199 |
| 16 | 2015 | 182 | |
| 17 | 2019 | 177 | |
| 18 | 2011 | 172 | |
| 19 | 2014 | 165 | |
| 20 | 2020 | 162 |
About Ryan J. Sullivan
Ryan J. Sullivan is a scholar working on Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 402 papers that have together received 13.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (160 papers), Melanoma and MAPK Pathways (116 papers), CAR-T cell therapy research (90 papers), Immunotherapy and Immune Responses (49 papers), Cutaneous Melanoma Detection and Management (40 papers), Colorectal Cancer Treatments and Studies (30 papers), Cancer Genomics and Diagnostics (27 papers) and Brain Metastases and Treatment (24 papers). The work is most often cited by research in Oncology (8.6k citations), Immunology (2.8k citations), Genetics (633 citations), Cancer Research (836 citations) and Pulmonary and Respiratory Medicine (1.6k citations). Ryan J. Sullivan has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Keith T. Flaherty, Donald P. Lawrence, Douglas B. Johnson, Kerry L. Reynolds, Justine V. Cohen, Jeffrey S. Weber, Alexander M. Menzies, Alexander T. Faje, Riley Fadden and F. Stephen Hodi. Their work appears in journals such as Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Cancer Research, The Oncologist and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.